Paulson & CO. Inc. purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the second quarter, according to its most recent disclosure with the SEC. The firm purchased 111,100 shares of the biopharmaceutical company’s stock, valued at approximately $1,424,000. Paulson & CO. Inc. owned approximately 0.08% of Halozyme Therapeutics at the end of the most recent quarter.
Other institutional investors also recently modified their holdings of the company. Ameritas Investment Partners Inc. purchased a new position in Halozyme Therapeutics in the 1st quarter valued at about $122,000. Teacher Retirement System of Texas purchased a new position in Halozyme Therapeutics in the 2nd quarter valued at about $129,000. Arrowstreet Capital Limited Partnership purchased a new position in Halozyme Therapeutics in the 2nd quarter valued at about $131,000. Prudential Financial Inc. lifted its stake in Halozyme Therapeutics by 8.7% in the 2nd quarter. Prudential Financial Inc. now owns 11,726 shares of the biopharmaceutical company’s stock valued at $150,000 after buying an additional 940 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd purchased a new position in Halozyme Therapeutics in the 2nd quarter valued at about $171,000. 85.06% of the stock is currently owned by hedge funds and other institutional investors.
HALO has been the topic of a number of research reports. Deutsche Bank AG raised their price target on shares of Halozyme Therapeutics to $20.00 and gave the company a “buy” rating in a research note on Friday, September 15th. Zacks Investment Research raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a research note on Friday, August 25th. Piper Jaffray Companies set a $20.00 price target on shares of Halozyme Therapeutics and gave the company a “buy” rating in a research note on Thursday, August 10th. Canaccord Genuity set a $16.00 price target on shares of Halozyme Therapeutics and gave the company a “buy” rating in a research note on Wednesday, July 26th. Finally, BidaskClub lowered shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, July 1st. One research analyst has rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $17.00.
TRADEMARK VIOLATION WARNING: “Paulson & CO. Inc. Invests $1.42 Million in Halozyme Therapeutics, Inc. (HALO)” was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this report on another site, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this report can be viewed at https://sportsperspectives.com/2017/10/18/paulson-co-inc-invests-1-42-million-in-halozyme-therapeutics-inc-halo.html.
Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.02. The business had revenue of $33.80 million during the quarter, compared to analysts’ expectations of $31.76 million. During the same period last year, the company earned ($0.21) EPS. The firm’s revenue for the quarter was up 1.2% on a year-over-year basis.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.
Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO).
Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.